- This topic is empty.
-
AuthorPosts
-
2026-11-19 at 5:48 pm #85144
Why Microbial Expression Systems Are Reshaping Biologics Manufacturing
The biopharmaceutical industry continues to confront persistent manufacturing challenges: low yields and stability issues in mammalian expression systems, severe aggregation in scFv/Fab fragments, high biopharmaceutical manufacturing costs, and complex regulatory hurdles for market entry across the US, China, and EU. For companies seeking an alternative path, microbial CRDMO services offer a specialized solution built around E. coli and yeast expression systems rather than generic mammalian platforms.
Yaohai Bio-Pharmaceutical (brand name Yaohai Bio-Pharma), founded in 2010, has positioned itself as a Microbial CRDMO — a Contract Research, Development, and Manufacturing Organization specializing exclusively in microbial expression systems. The company’s strategic positioning centers on providing a one-stop solution from R&D and process development through GMP manufacturing, addressing the industry pain points described above directly rather than through incremental fixes to mammalian-based platforms.
What Makes Microbial Expression a Viable Alternative
Mammalian expression systems have long dominated biologics manufacturing, but they carry well-documented limitations: lower yields, stability concerns, and higher production overhead. Yaohai Bio-Pharma’s technology platform — comprising an E. coli expression platform, a yeast expression platform, the RNASUP mRNA platform, and LNP encapsulation technologies including SORT LNP and AbLNP — offers an alternative built on microbial systems specialization.
A specific technical challenge in antibody fragment development is aggregation in scFv/Fab fragments, which complicates both yield and downstream purification. Yaohai Bio-Pharma addresses this through proprietary refolding technology, with project execution teams led by Ph.D. experts. This capability directly targets a problem that mammalian-based approaches do not inherently solve.

Who Needs End-to-End Biologics CRDMO Support
Target customers for this type of service span global biopharmaceutical companies, biotech startups, research institutes, and universities. These organizations typically pursue one or more of the following biologic modalities, all producible through Yaohai Bio-Pharma’s microbial expression systems:
- Recombinant Protein — produced via E. coli and yeast platforms as an alternative to mammalian systems, addressing low yield and stability challenges inherent to mammalian-based production.
- Plasmid DNA — GMP-grade production supporting viral vector construction and cell therapy applications, with high-purity pDNA meeting the requirements of AAV vector programs.
- Nanobody (VHH) — clinical-grade production achieving ultra-high yield and superior stability, suited to oncology therapeutics development.
- Vaccines — GMP manufacturing at commercial scale, operating under ISO-certified and EU QP-audited facilities.
- mRNA — produced through the RNASUP mRNA platform, supported by LNP encapsulation technologies (SORT LNP and AbLNP) to address mRNA delivery and storage stability challenges.
- circRNA (Circular RNA) — development support for gene therapy applications through the microbial platform.
How the End-to-End Service Model Works
End-to-end biologics manufacturing under a CRDMO model means integrating multiple stages that are often fragmented across separate vendors elsewhere. Yaohai Bio-Pharma structures this integration across four platforms: CMC Process Development, GMP Manufacturing, Quality Control, and Global Regulatory Affairs.
Early R&D and process development begins with molecular design and construct development, strain development and cell bank establishment, and upstream/downstream process development using research-grade materials. This stage directly supports strain construction, screening, optimization, and characterization for recombinant proteins, nanobodies (VHHs), and plasmid DNA.
Process scale-up and CMC development follows, encompassing fermentation and purification scale-up, process characterization and optimization, analytical method development and validation, and formulation development with technology transfer. Scale-up capabilities extend up to 2,000L fermentation, supported by QbD- and DoE-based process development approaches.
GMP manufacturing and clinical supply cover GMP drug substance manufacturing, clinical-stage material supply, quality control with batch release support, and drug product manufacturing including sterile fill-finish services for applicable products. Yaohai Bio-Pharma operates 7,500L total drug substance capacity across 5 production lines (ranging from 50L small scale to 2000L large scale) and 2 drug product fill-finish lines.
Regulatory support and commercial manufacturing complete the cycle, with CMC documentation and regulatory submission support, process validation and technology transfer, and commercial-scale manufacturing for qualified products. The company maintains a track record in US-China dual submissions as well as Australian filings, with successful European and Australian regulatory registrations for clinical trials also documented.
Quantifying the Manufacturing Advantage
Several operational metrics characterize the depth of this CRDMO approach. Compared to other CDMO companies, Yaohai Bio-Pharma reports an average of 20% cost savings and 30% time savings for clients — a direct outcome of integrating R&D, process development, and GMP manufacturing within one organization rather than coordinating across multiple vendors.
Delivery reliability is reflected in a 98% technology transfer success rate, a 98% successful project delivery rate, and a 95% client retention rate. These figures correspond with a service history that includes 200+ successful projects completed, support for 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects. Since 2022, the company has supported over 800 RNA projects for universities and biotechs.
Quality assurance is anchored by triple ISO-certified and EU QP-audited facilities, along with 50+ analytical methods covering protein identity, purity, concentration, potency, and impurity analysis, physicochemical and microbiological testing, stability studies, specification development, and batch release testing.
Addressing Regulatory Complexity Across Markets
Global market entry remains one of the more complex aspects of biologics development, particularly for companies pursuing simultaneous approval pathways. Yaohai Bio-Pharma’s Global Regulatory Affairs platform supports IND/BLA submissions and clinical trial registrations, with documented cases including a successful US-China dual submission for a biopharmaceutical asset and successful European and Australian regulatory registrations for clinical trials. This capability is particularly relevant given the company’s business coverage across the USA, China, Europe (EU), and Australia.
A Practical Framework for Evaluating Microbial CRDMO Partners
Organizations evaluating a microbial CRDMO partner for end-to-end biologics manufacturing should consider several factors illustrated by Yaohai Bio-Pharma’s capability structure: breadth of expression platforms (E. coli, yeast, mRNA, LNP encapsulation), proven scale-up capacity, documented technology transfer and delivery success rates, quality certifications relevant to target markets, and demonstrated regulatory experience across the jurisdictions where approval is sought.
For companies navigating the specific challenges of mammalian system limitations, antibody fragment aggregation, manufacturing cost pressure, and multi-region regulatory complexity, a specialized microbial CRDMO model — integrating R&D, process development, GMP manufacturing, quality control, and global regulatory affairs under one framework — represents a structured approach to addressing these interconnected challenges within a single service relationship.

http://www.yaohaibio-pharma.com
Yaohai Bio-Pharma -
AuthorPosts
- You must be logged in to reply to this topic.